Invesco’s VYNE Therapeutics VYNE Stock Holding History

Invesco’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-340	Closed	-$39K	–	3951
2020 Q4	$39K	Buy	+340	New	+$42.7K	﹤0.01%	3752

Other funds holding VYNE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

HVC

Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

Invesco's VYNE Position: Q1 2021 in Review

Invesco sold out of VYNE Therapeutics (VYNE) in Q1 2021, closing a stake of 340 shares — an estimated $39K sold.

Invesco first reported a position in VYNE in Q4 2020 and held it in 1 quarter. The position peaked at $39K in Q4 2020. 89 funds tracked by Wall St. Rank hold VYNE as of Q1 2021.

Invesco reported no remaining VYNE Therapeutics position as of Q1 2021 after selling out during the quarter.
Invesco sold 340 VYNE Therapeutics shares in Q1 2021, an estimated $39K.
Invesco first reported a position in VYNE Therapeutics in Q4 2020 and held it in 1 quarter.
Invesco's VYNE Therapeutics position peaked at $39K in Q4 2020.
89 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2021.

Based on Invesco's 13F filing for Q1 2021, filed 17 May 2021.